New drug shows promise for better heart function in lung disease patients
NCT ID NCT06409026
First seen Jan 29, 2026 · Last updated May 11, 2026 · Updated 14 times
Summary
This study tested whether the drug sotatercept, given for 36 weeks, can improve how the heart works during exercise and enhance quality of life in people with pulmonary arterial hypertension (PAH). Thirty adults with PAH took part. The goal was to see if the drug helps the heart pump more efficiently and deliver oxygen better to the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.